Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

2.59

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.09

EPS Last/This Y

-2.37

EPS This/Next Y

0.59

Price

90

Target Price

97

Analyst Recom

2.75

Performance Q

-3.92

Upside

N/A

Beta

1.19

Ticker: MRUS



19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23MRUS90N/AN/A0
2026-01-26MRUS90N/AN/A0
2026-01-27MRUS90N/AN/A0
2026-01-28MRUS90N/AN/A0
2026-01-29MRUS90N/AN/A0
2026-01-30MRUS90N/AN/A0
2026-02-02MRUS90N/AN/A0
2026-02-03MRUS90N/AN/A0
2026-02-04MRUS90N/AN/A0
2026-02-05MRUS90N/AN/A0
2026-02-06MRUS90N/AN/A0
2026-02-09MRUS90N/AN/A0
2026-02-10MRUS90N/AN/A0
2026-02-11MRUS90N/AN/A0
2026-02-12MRUS90N/AN/A0
2026-02-13MRUS90N/AN/A0
2026-02-17MRUS90N/AN/A0
2026-02-18MRUS90N/AN/A0
2026-02-20MRUS90N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1



No data found



No data found

Last Quarter Act. EPS​

-1.23

Avg. EPS Est. Current Quarter

-1.02

Avg. EPS Est. Next Quarter

-1.32

Insider Transactions

5.63

Institutional Transactions

Beta

1.19

Average Sales Estimate Current Quarter

9

Average Sales Estimate Next Quarter

11

Fair Value

Quality Score

19

Growth Score

36

Sentiment Score

73

Actual DrawDown %

7.3

Max Drawdown 5-Year %

-60.4

Target Price

97

P/E

Forward P/E

PEG

P/S

120.59

P/B

8.81

P/Free Cash Flow

EPS

-5.33

Average EPS Est. Cur. Y​

-5.72

EPS Next Y. (Est.)

-5.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-673.31

Relative Volume

Return on Equity vs Sector %

-76.5

Return on Equity vs Industry %

-61.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

1.9
Merus N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 260
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
stock quote shares MRUS – Merus N.V Stock Price stock today
news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch MRUS – Merus N.V yahoo finance google finance
stock history MRUS – Merus N.V invest stock market
stock prices MRUS premarket after hours
ticker MRUS fair value insiders trading